Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI
Brief Summary: The incidence of stent restenosis in the setting of primary angioplasty is particularly high, reaching a rate of 27% In the last years the introduction of drug-eluting stents has drastically reduced the incidence of restenosis in patients not requiring urgent revascularization. Whether drug-eluting stenting might constitute the new optimal therapy for patients with an acute myocardial infarction is unknown. To be able to answer this question, we designed a randomized trial in which patients with an acute myocardial infarction eligible for treatment with primary angioplasty and abciximab were randomized to receive either a rapamicine-eluting stent or a conventional bare stent.


Options:
A: Inclusion Criteria:

* Men and women \>18 years with stable angina pectoris or acute coronary syndrome
* The patient has consented to participate and has signed the patient informed consent form
* All lesions requiring intervention in one or more native coronary artery/coronary artery by-pass graft are amendable for implantation of drug-eluting stents only, or bare-metal stents only.
* The patient has a unique 11-digit Norwegian person number, is able to communicate in Norwegian, and is expected not to emigrate during study follow-up.

Exclusion Criteria:

* Previous implantation of a coronary bare metal stent or coronary drug eluting stent
* Planned intervention of a bifurcation lesion with overlapping 2-stent technique
* The patient has a serious medical condition (other than coronary artery disease) with a life expectancy less than 5 years
* The patient is currently participating in another randomized trial that clinically interferes with the present trial, or requires coronary angiography or other coronary artery imaging procedures
* Hypersensitivity or allergies to drugs or components in use with percutaneous coronary intervention
* Contraindications for treatment with clopidogrel/ticlid for 9-12 months
* Patient is receiving chronic anticoagulation therapy (e.g., warfarin, heparin)
B: Inclusion Criteria:

* Clinical symptoms of STEMI, with initial onset of chest pain within the past 12 hours, an ECG demonstrating \> 0.1 mV ST-segment elevation in 2 or more contiguous leads or documented new left bundle-branch block and were suitable candidates for percutaneous revascularization.

Exclusion Criteria:

* Active internal bleeding or a history of bleeding diathesis within the previous 30 days
* An history of intracranial hemorrhage
* Intracranial neoplasm
* Arteriovenous malformation or aneurysm
* Known allergy to sirolimus
* Paclitaxel
* Heparin, aspirin, or clopidogrel
* An history of stroke within 30 days or any history of hemorrhagic stroke
* History, symptoms, or findings suggestive of aortic dissection, fibrinolytic therapy within 24 hours
* History of thrombocytopenia, pregnancy, patients on warfarin or acenocoumarol within the last seven days
* Inability to obtain the informed consent
C: Inclusion Criteria:

* Acute onset typical chest pain of \< 12 hours' duration
* ST-elevation of \> 4 mm (1mm = 0.1 mV) in contiguous leads of the electrocardiogram
* High grade stenosis or occlusion of a native major coronary artery that can be crossed with a soft or intermediate tip guidewire
* Possibility to perform distal protection of the infarct-related artery

Exclusion Criteria:

* History of previous myocardial infarction
* Use of fibrinolytic agents for the index infarction
* Left main stenosis
* Heavily calcification of abdominal aorta or occlusive iliofemoral disease hampering access to the coronary ostias by the femoral route
* Known renal failure
* Other significant cardiac disease
* Other severe disease with an expected survival \< 1 year
* Known allergy against clopidogrel or contrast media that can not be avoided/limited by medication
* Linguistic difficulties needing an interpreter
* Gastrointestinal bleeding within 1 month
* Childbearing potential or pregnancy
* Participation in another study
D: Inclusion Criteria:

Inclusion criteria were an age of more than 18 years, the presence for at least 30 minutes but less than 12 hours of symptoms consistent with acute myocardial infarction, and the presence of ST-segment elevation in at least two contiguous leads or left bundle-branch block.

-

Exclusion Criteria:

Patients were excluded if they were in cardiogenic shock (defined as systolic blood pressure of less than 80 mm Hg for more than 30 minutes or the need for intravenous pressors or intraaortic-balloon counterpulsation); had a history of bleeding diathesis; had a history of leukopenia, thrombocytopenia, or severe hepatic or renal dysfunction; had a noncardiac illness associated with a life expectancy of less than one year; were participating in another study; or were unable to give informed consent owing to prolonged cardiopulmonary resuscitation.

-

Answer: D